Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Meet the Expert: Daniel Seymour
Daniel Seymour - BIO Ventures for Global Health, Seattle, USA
Meet the Expert: Daniel Seymour ( Daniel Seymour - BIO Ventures for Global Health, Seattle, USA )
1 Jul 2020
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )
30 Jun 2020
Treating patients with multiple myeloma in the real world
Dr Ajai Chari and Prof Roman Hájek
Treating patients with multiple myeloma in the real world ( Dr Ajai Chari and Prof Roman Hájek )
26 Jun 2020
ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer
Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany
ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer ( Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany )
24 Jun 2020
The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blina...
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blinatumomab ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jun 2020
MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemot...
Dr Fatima Cardoso - Champalimaud Clinical Center, Lisbon, Portugal
MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemotherapy use in breast cancer ( Dr Fatima Cardoso - Champalimaud Clinical Center, Lisbon, Portugal )
18 Jun 2020
Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma
Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA
Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma ( Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA )
16 Jun 2020
ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for ...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )
15 Jun 2020
Background of the KEYLYNK-007 trial for advanced solid tumours
Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
Background of the KEYLYNK-007 trial for advanced solid tumours ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )
13 Jun 2020
US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-cla...
Dr Sudhir Manda - Arizona Oncology / US Oncology Research, Tucson, USA
US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib ( Dr Sudhir Manda - Arizona Oncology / US Oncology Research, Tucson, USA )
13 Jun 2020
OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase c...
Prof Jorge Cortes - Augusta University, Augusta, USA
OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase chronic myeloid leukaemia ( Prof Jorge Cortes - Augusta University, Augusta, USA )
13 Jun 2020
VIALE-A: Venetoclax with or without in treatment-naïve patients with acute myelo...
Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA
VIALE-A: Venetoclax with or without in treatment-naïve patients with acute myeloid leukaemia ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )
13 Jun 2020